- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2019
- Public Summary Document (PSD) March 2019 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2019 PBAC Meeting - Word
Atezolizumab and bevacizumab – March 2019
Atezolizumab and Bevacizumab: atezolizumab: Solution concentrate for I.V. infusion 1200 mg in 20 mL; bevacizumab: Solution for I.V. infusion 100 mg in 4 mL, Solution for I.V. infusion 400 mg in 16 mL; Tecentriq® and Avastin®
Last updated
26 July 2019